UNIGE document Scientific Article
previous document  unige:83904  next document
add to browser collection
Title

Role of MIF/CD74 signaling pathway in the development of pleural mesothelioma

Authors
Published in Oncotarget. 2016, vol. 7, no. 10, p. 11512-25
Abstract Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine implicated in acute and chronic inflammatory diseases. MIF is overexpressed in various tumors. It displays a number of functions that provide a direct link between the process of inflammation and tumor growth. Our group recently identified the MIF-receptor CD74 as an independent prognostic factor for overall survival in patients with malignant pleural mesothelioma. In the present study, we compared the levels of expression of MIF and CD74 in different human mesothelioma cell lines and investigated their physiopathological functions in vitro and in vivo. Human mesothelioma cells expressed more CD74 and secreted less MIF than non tumoral MeT5A cells, suggesting a higher sensitivity to MIF. In mesothelioma cells, high MIF levels were associated with a high multiplication rate of cells. In vitro, reduction of MIF or CD74 levels in both mesothelioma cell lines showed that the MIF/CD74 signaling pathway promoted tumor cell proliferation and protected MPM cells from apoptosis. Finally, mesothelioma cell lines expressing high CD74 levels had a low tumorigenic potential after xenogeneic implantation in athymic nude mice.
Keywords CancerPleuraMesotheliomaMacrophage migration inhibitory factor (MIF)CD74
Identifiers
PMID: 26883190
Full text
Structures
Research groups Ligue Pulmonaire Genevoise et Ligue genevoise contre le cancer
Mésothéliome pleural malin (944)
Citation
(ISO format)
D'AMATO DOS REIS BRITO, Cintia et al. Role of MIF/CD74 signaling pathway in the development of pleural mesothelioma. In: Oncotarget, 2016, vol. 7, n° 10, p. 11512-25. https://archive-ouverte.unige.ch/unige:83904

182 hits

65 downloads

Update

Deposited on : 2016-05-27

Export document
Format :
Citation style :